Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29928434 | 0.95 | FURIN (0.93) | FURIN | |
| SCHEMBL21550653 | 0.95 | FURIN (0.93) | FURIN | |
| SCHEMBL23364557 | 0.94 | FURIN (0.82) | FURIN | |
| SCHEMBL29890827 | 0.94 | FURIN (0.82) | FURIN | |
| SCHEMBL29928784 | 0.94 | FURIN (0.81) | FURIN | |
| SCHEMBL21551332 | 0.94 | FURIN (0.81) | FURIN | |
| SCHEMBL21550595 | 0.92 | FURIN (0.83) | FURIN | |
| SCHEMBL29928593 | 0.92 | FURIN (0.83) | FURIN | |
| SCHEMBL21551263 | 0.92 | FURIN (0.85) | FURIN | |
| SCHEMBL21551271 | 0.91 | FURIN (1.00) | FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | claimed |
| US-20230011571-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | BP ASSET V, INC. (US) | 2023-01-12 | — | — | US | claimed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | claimed |
| EP-4058021-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | BP Asset V, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| WO-2021097009-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | BP ASSET V, INC. (US) | 2021-05-20 | — | — | WO | claimed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | claimed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | claimed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | FURIN 1/4885 |
| US-20230011571-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | FURIN, LGMN, PLAU | FURIN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.